NCT03077347

Brief Summary

The purpose of this study is to better understand the neural correlates of cognitive control (CC) deficits in schizophrenia and determine how these mechanisms can be modulated by transcranial direct current stimulation (tDCS). CC is a critical neurocognitive process that is required for flexible, directed thought and action based on goals and intentions. Identifying and developing paradigms to improve CC is therefore a mental health priority. Current theories of CC postulate that recruitment of the dorsolateral prefrontal cortex (DLPFC) is essential for this process by maintaining high-level information that it can then use to orchestrate patterns of activation in other brain networks to support optimal performance. tDCS is a safe, noninvasive method of modulating regional brain excitability via brief (15-20 m) application of a weak (1-2 mA) current. The goal of the proposed experiments is to combine tDCS with functional magnetic resonance imaging (fMRI) to test the hypotheses that 1) acute tDCS over the DLPFC can improve performance during a CC task (the dot pattern expectancy (DPX) variant of the AX-Continuous Performance Task) in schizophrenia patients and healthy control subjects, and 2) acute tDCS over the DLPFC can increase recruitment of the DLPFC during the DPX. Effects of tDCS on brain functional connectivity (during CC as well as during the resting state) will also be examined, as well as effects on an episodic memory task. The current study will be the first to use functional magnetic resonance imaging (fMRI) to examine the effects of tDCS on the neuronal mechanisms of CC in schizophrenia, and has potentially important implications for therapeutic development for this treatment refractory yet disabling aspect of the illness.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable schizophrenia

Timeline
Completed

Started Apr 2017

Longer than P75 for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 1, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 10, 2017

Completed
22 days until next milestone

Study Start

First participant enrolled

April 1, 2017

Completed
5.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 23, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 23, 2023

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

June 13, 2024

Completed
Last Updated

June 13, 2024

Status Verified

October 1, 2023

Enrollment Period

5.9 years

First QC Date

March 1, 2017

Results QC Date

March 26, 2024

Last Update Submit

May 18, 2024

Conditions

Keywords

SchizophreniaTranscranial Direct Current StimulationtDCSCognitive ControlfMRIDorsolateral Prefrontal Cortex

Outcome Measures

Primary Outcomes (2)

  • Dorsolateral Prefrontal Cortex Response

    Blood oxygen level-dependent response of the dorsolateral prefrontal cortex during a cognitive control task (Dot-Probe Expectancy Task)

    Assessment will begin immediately following stimulation and last for up to an hour.

  • Behavioral Response

    Cognitive control-related performance (d-prime context) associated with the task (Dot-Probe Expectancy Task). The d-prime context index was calculated by computing a d-prime index from hits on AX trials and false alarms on BX trials as Z(H) - Z(F), with H representing hits on AX trials, F representing false alarms on BX trials, and Z representing the z-transform of a value. Positive d-prime values indicate more cognitive control, and negative values indicate less cognitive control.

    Assessment will begin immediately following stimulation and last for up to an hour.

Study Arms (2)

Sham Followed by Experimental Stimulation

OTHER

Sham stimulation administered followed by 24-48 hour washout, then experimental stimulation. Experimental Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex Placebo Comparator. 1 minute of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19 minutes of sham stimulation.

Device: Transcranial Direct Current Stimulation

Experimental Stimulation Followed by Sham

OTHER

Experimental stimulation administered followed by 24-48 hour washout, then sham stimulation. Experimental Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex Placebo Comparator. 1 minute of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19 minutes of sham stimulation.

Device: Transcranial Direct Current Stimulation

Interventions

In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Also known as: tDCS
Experimental Stimulation Followed by ShamSham Followed by Experimental Stimulation

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Sufficient English literacy so as to be able to understand and complete cognitive tasks.
  • The ability to give valid informed consent.
  • Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (for patient group)
  • Stable outpatient or partial hospital status (for patient group)

You may not qualify if:

  • Psychiatric medication changes in the prior month (for patient group)
  • No psychiatric medication changes anticipated in the upcoming month (for patient group)
  • Intelligence Quotient (IQ) \< 70; IQ will be measured by administering the Wechsler Abbreviated Scale of Intelligence (WASI) test.
  • People under the age of 18
  • Pregnant Women
  • Prisoners
  • Pacemakers
  • Implanted brain stimulators
  • Implanted defibrillator
  • Metallic implants
  • Skin damage or skin conditions such as eczema at the sites where electrodes will be placed
  • Dreadlocks or other hair styles hindering the placement of tDCS electrodes
  • Cranial pathologies
  • Head trauma
  • Epilepsy
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Imaging Research Center, University of California Davis Medical Center

Sacramento, California, 95817, United States

Location

MeSH Terms

Conditions

Schizophrenia

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Results Point of Contact

Title
Tiffany T . Norris
Organization
University of CA Davis Health

Study Officials

  • Cameron Carter, M.D.

    University of California, Davis

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Sham Stimulation followed by Direct Current Stimulation or Vice-Versa
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2017

First Posted

March 10, 2017

Study Start

April 1, 2017

Primary Completion

February 23, 2023

Study Completion

February 23, 2023

Last Updated

June 13, 2024

Results First Posted

June 13, 2024

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will share

Select data from this study may be submitted to the National Institute of Mental Health Data Archive (NDA). NDA is a data repository run by the National Institute of Mental Health (NIMH) that allows researchers studying mental illness to collect and share de-identified information with each other. The data repository is accessible only to qualified investigators. All subject data will be de-identified (subject names will not be used) and each subject will have a separate identifier called a Global Unique Identifier (GUID) to remove any possibility that "the identities of the subjects cannot be readily ascertained or otherwise associated with the data by the repository staff or secondary data users" (45 Code of Federal Regulations, 46.102).

Locations